Business Context and Reporting Period
Company: Xcyte Therapies, Inc. (Note: Request metadata listed "Bio Green Med Solution, Inc.", but the filing text identifies the registrant as Xcyte Therapies, Inc.)
Filing Type: Form 10-K
Period Ended: December 31, 2005
Xcyte Therapies, Inc. was a biotechnology company focused on developing therapeutic products using its proprietary Xcellerate Technology to activate T cells. In July 2005, the company announced it was exploring strategic alternatives, discontinued its clinical development program, and substantially reduced its workforce to five employees by year-end. On December 15, 2005, Xcyte entered into a Stock Purchase Agreement to acquire Cyclacel Ltd. (a reverse merger) and an Asset Purchase Agreement to sell its Xcellerate Technology to Invitrogen Corporation for $5 million. Stockholders approved these transactions in March 2006, with the company planning to rename itself Cyclacel Pharmaceuticals, Inc.
Key Financial Metrics
| Metric | 2005 | 2004 |
|---|---|---|
| Total Revenue | $813,000 | $62,000 |
| Net Loss | $(29,416,000) | $(39,588,000) |
| Net Loss Applicable to Common Stockholders | $(29,416,000) | $(48,561,000) |
| Research & Development Expenses | $13,772,000 | $19,698,000 |
| General & Administrative Expenses | $9,669,000 | $6,876,000 |
| Restructuring & Asset Impairment Charges | $7,004,000 | $0 |
| Cash, Cash Equivalents & Short-term Investments | $20,529,000 | $47,318,000 |
| Working Capital | $15,703,000 | $43,947,000 |
| Accumulated Deficit | $(155,599,000) | $(126,183,000) |
Material Changes Versus Prior Period
- Revenue Surge: Revenue increased significantly from $62,000 in 2004 to $813,000 in 2005. This was primarily due to the recognition of $809,000 in remaining deferred revenue from a terminated collaboration with Fresenius Biotech GmbH, rather than operational growth.
- Restructuring Costs: The company recorded $7.0 million in non-recurring charges in 2005, including a $4.2 million asset impairment loss, $2.6 million in facility-related restructuring costs (abandoning the Bothell manufacturing facility), and $2.7 million in workforce reduction costs. There were no such charges in 2004.
- Expense Reduction: R&D expenses decreased by 30% ($5.9 million) due to the discontinuation of clinical trials. However, G&A expenses increased by 41% ($2.8 million) driven by professional fees related to strategic alternatives and severance costs.
- Liquidity Decline: Cash and investments dropped from $47.3 million to $20.5 million, reflecting operating cash outflows of $21.5 million and the repayment of equipment financing debt.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Transactions: The company's future is contingent upon the closing of the reverse merger with Cyclacel and the asset sale to Invitrogen, both anticipated to close by March 31, 2006. Upon closing, the company will cease its current operations and adopt Cyclacel's business model focused on cell cycle biology drugs.
Risks and Contingencies:
- Delisting Risk: Xcyte faced delisting from the Nasdaq National Market due to its stock price falling below the $1.00 minimum bid price. Listing was conditionally continued pending the reverse merger and a 1-for-10 reverse stock split.
- State Tax Assessment: The company received a $1 million sales tax assessment from the State of Washington regarding the high-technology sales tax deferral program. Management accrued $270,000 as a liability but is appealing the assessment, estimating a potential loss range of $270,000 to $1 million.
- Derivative Liability: A $2.1 million liability exists related to the dividend make-whole feature of convertible preferred stock. Fluctuations in the fair value of this derivative impacted net loss by $336,000 in 2005.
- Going Concern: While the company prepared financial statements assuming a going concern based on the pending merger, it noted that without the transaction, it might be forced to liquidate.
Key Facts for Investor Verification
- Transaction Closing: Verify the status of the Stock Purchase Agreement with Cyclacel and the Asset Purchase Agreement with Invitrogen, as the company's existence and business model depend entirely on these closings.
- Reverse Stock Split: Confirm the execution of the 1-for-10 reverse stock split approved by shareholders, which is a condition for maintaining Nasdaq listing.
- Asset Sale Proceeds: Monitor the final settlement of the $5 million asset sale to Invitrogen, noting the potential for a post-closing adjustment requiring a refund of up to $1 million.
- Tax Liability Resolution: Track the outcome of the appeal regarding the Washington State sales tax assessment, which could result in an additional liability up to $730,000 beyond the accrued amount.
- Employee Retention: Verify the retention of the remaining five employees and the fulfillment of retention bonuses tied to the successful consummation of the merger.